Krebs Von Den Lungen-6 As A Biomarker for Disease Severity Assessment in Interstitial Lung Disease: A Comprehensive Review

References

• Behr J . Approach to the diagnosis of interstitial lung disease. Clin. Chest Med.33(1), 1–10 (2012).
   PubMed Web of Science ®Google Scholar
• Collins J . CT signs and patterns of lung disease. Radiol. Clin. North Am.39(6), 1115–1135 (2001).
   PubMed Web of Science ®Google Scholar
• Meyer KC . The role of bronchoalveolar lavage in interstitial lung disease. Clin. Chest Med.25(4), 637–649 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer KC , RaghuG, BaughmanRPet al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med.185(9), 1004–1014 (2012).
   PubMed Web of Science ®Google Scholar
• Kohno N , KyoizumiS, AwayaY, FukuharaH, YamakidoM, AkiyamaM. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest96(1), 68–73 (1989).
   PubMed Web of Science ®Google Scholar
• Kobayashi J , KitamuraS. KL-6: a serum marker for interstitial pneumonia. Chest108(2), 311–315 (1995).
   PubMed Web of Science ®Google Scholar
• Kohno N , AwayaY, OyamaTet al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am. Rev. Respir. Dis.148(3), 637–642 (1993).
   PubMedGoogle Scholar
• Balakrishnan Menon MT , AryaGopi, PraveenRaj, KunjPanwar. Serum krebs von den lungen-6 (KL-6): a promising biomarker in sarcoidosis. MOJ Curr Res & Rev.1(2), 45–47 (2018).
   Google Scholar
• Kohno N , AkiyamaM, KyoizumiS, HakodaM, KobukeK, YamakidoM. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn. J. Clin. Oncol.18(3), 203–216 (1988).
   PubMed Web of Science ®Google Scholar
• Kamiya K , WatanabeM, KohnoMet al. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small-cell lung cancer. Respirology16(6), 976–982 (2011).
   PubMed Web of Science ®Google Scholar
• Briassoulis G , StefanakiK, PeristeriI, EndohY, HatzisT. Is KL-6 a serum indicator of early pulmonary fibrosis in childhood cancer patients?Med. Pediatr. Oncol.40(1), 44–47 (2003).
   PubMedGoogle Scholar
• Kohno N , HamadaH, FujiokaS, HiwadaK, YamakidoM, AkiyamaM. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest102(1), 117–122 (1992).
   PubMed Web of Science ®Google Scholar
• Hamada H , KohnoN, AkiyamaM, HiwadaK. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest101(3), 858–860 (1992).
   PubMed Web of Science ®Google Scholar
• Wakamatsu K , NagataN, KumazoeHet al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir. Investig.55(1), 16–23 (2017).
   PubMed Web of Science ®Google Scholar
• Yokoyama A , KondoK, NakajimaMet al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology11(2), 164–168 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa N , HattoriN, YokoyamaA, KohnoN. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig.50(1), 3–13 (2012).
   PubMedGoogle Scholar
• Ohnishi H , YokoyamaA, KondoKet al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am. J. Respir. Crit. Care Med.165(3), 378–381 (2002).
   PubMed Web of Science ®Google Scholar
• Horimasu Y , HattoriN, IshikawaNet al. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir. Med.106(12), 1756–1764 (2012).
   PubMed Web of Science ®Google Scholar
• Bonella F , LongX, OhshimoSet al. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet J. Rare Dis.11, 48 (2016).
   PubMed Web of Science ®Google Scholar
• Raghu G , CollardHR, EganJJet al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med.183(6), 788–824 (2011).
   PubMed Web of Science ®Google Scholar
• Drakopanagiotakis F , WujakL, WygreckaM, MarkartP. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol.68-69, 404–421 (2018).
   PubMed Web of Science ®Google Scholar
• Bonella F . Serum KL-6 levels correlate with response to pirfenidone in idiopathic pulmonary fibrosis.Am. J. Respir. Crit Care Med.191, A4398 (2015).
   Web of Science ®Google Scholar
• Maher TM , StowasserS, NishiokaYet al. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomized placebo-controlled INMARK(R)trial. BMJ Open Respir. Res.5(1), e000325 (2018).
   PubMedGoogle Scholar
• Ishii H , KushimaH, KinoshitaY, FujitaM, WatanabeK. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin. Respir. J.12(9), 2411–2418 (2018).
   PubMed Web of Science ®Google Scholar
• Satoh H , KurishimaK, IshikawaH, OhtsukaM. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J. Intern. Med.260(5), 429–434 (2006).
   PubMed Web of Science ®Google Scholar
• Bergantini L , BargagliE, CameliPet al. Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib. Respir. Investig.57(3), 290–291 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu C , ZhaoYB, KongLF, LiZH, KangJ. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases]. Zhonghua Jie He He Hu Xi Za Zhi39(2), 93–97 (2016).
   PubMedGoogle Scholar
• Nakamura M , OkamotoM, FujimotoKet al. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. Ann. Transl. Med.7(12), 262 (2019).
   PubMed Web of Science ®Google Scholar
• Okuda R , HagiwaraE, BabaT, KitamuraH, KatoT, OguraT. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir. Med.107(9), 1431–1437 (2013).
   PubMed Web of Science ®Google Scholar
• Koga Y , HachisuY, TsurumakiHet al. Pirfenidone improves familial idiopathic pulmonary fibrosis without affecting serum periostin levels. Medicina (Kaunas)55(5), 161 (2019).
   PubMed Web of Science ®Google Scholar
• Ohshimo S , IshikawaN, HorimasuYet al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir. Med.108(7), 1031–1039 (2014).
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y , KawashimaT, KuwabaraRet al. Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther.32, 1–6 (2015).
   PubMed Web of Science ®Google Scholar
• Baughman RP , LowerEE, GibsonK. Pulmonary manifestations of sarcoidosis. Presse Med.41(6 Pt 2), e289–e302 (2012).
   PubMedGoogle Scholar
• Costabel U , BonellaF, OhshimoS, GuzmanJ. Diagnostic modalities in sarcoidosis: BAL, EBUS and PET. Semin. Respir. Crit. Care Med.31(4), 404–408 (2010).
   PubMed Web of Science ®Google Scholar
• Janssen R , SatoH, GruttersJCet al. Study of Clara cell 16, KL-6 and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest124(6), 2119–2125 (2003).
   PubMed Web of Science ®Google Scholar
• Kitaichi N , ArigaT, KaseS, YoshidaK, NambaK, OhnoS. Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis. Graefes Arch. Clin. Exp. Ophthalmol.244(4), 433–437 (2006).
   PubMed Web of Science ®Google Scholar
• Bergantini L , BianchiF, CameliPet al. Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme and KL-6. Dis. Markers2019, 8565423 (2019).
   PubMed Web of Science ®Google Scholar
• Miyoshi S , HamadaH, KadowakiTet al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest137(6), 1391–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Kunitake R , KuwanoK, YoshidaKet al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration68(5), 488–495 (2001).
   PubMed Web of Science ®Google Scholar
• d’Alessandro M . CarleoA. CameliPet al. BAL biomarkers' panel for differential diagnosis of interstitial lung diseases. Clin. Exp. Med. doi:10.1007/s10238-020-00608-5 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• d’Alessandro M , CarleoA, CameliPet al. Correction to: BAL biomarkers' panel for differential diagnosis of interstitial lung diseases. ClinExp. Med. doi:10.1007/s10238-020-00613-8 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Patel AM , RyuJH, ReedCE. Hypersensitivity pneumonitis: current concepts and future questions. J. Allergy Clin. Immunol.108(5), 661–670 (2001).
   PubMed Web of Science ®Google Scholar
• Richerson HB , BernsteinIL, FinkJNet al. Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the subcommittee on hypersensitivity pneumonitis. J. Allergy Clin. Immunol.84(5 Pt 2), 839–844 (1989).
   PubMed Web of Science ®Google Scholar
• Nukui Y , YamanaT, MasuoMet al. Serum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis. PLoS ONE14(8), e0220462 (2019).
   PubMed Web of Science ®Google Scholar
• Okamoto T , FujiiM, FurusawaH, TsuchiyaK, MiyazakiY, InaseN. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir. Med.109(12), 1576–1581 (2015).
   PubMed Web of Science ®Google Scholar
• Takahashi T , MunakataM, OhtsukaYet al. Serum KL-6 concentrations in dairy farmers. Chest118(2), 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Vasakova M , MorellF, WalshS, LeslieK, RaghuG. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am. J. Respir. Crit. Care Med.196(6), 680–689 (2017).
   PubMed Web of Science ®Google Scholar
• Wuyts WA , DoomsC, VerledenGM. The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med.187(7), 777 (2013).
   PubMed Web of Science ®Google Scholar
• Antoniou KM , MargaritopoulosG, EconomidouF, SiafakasNM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur. Respir. J.33(4), 882–896 (2009).
   PubMed Web of Science ®Google Scholar
• Nakajima H , HarigaiM, HaraMet al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J. Rheumatol.27(5), 1164–1170 (2000).
   PubMed Web of Science ®Google Scholar
• Kodera M , HasegawaM, KomuraK, YanabaK, TakeharaK, SatoS. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum.52(9), 2889–2896 (2005).
   PubMed Web of Science ®Google Scholar
• Kubo M , IhnH, YamaneKet al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford)39(6), 632–636 (2000).
   PubMed Web of Science ®Google Scholar
• Hant FN , Ludwicka-BradleyA, WangHJet al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J. Rheumatol.36(4), 773–780 (2009).
   PubMed Web of Science ®Google Scholar
• Oyama T , KohnoN, YokoyamaAet al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung175(6), 379–385 (1997).
   PubMed Web of Science ®Google Scholar
• Bonella F , VolpeA, CaramaschiPet al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc. Diffuse Lung Dis.28(1), 27–33 (2011).
   PubMed Web of Science ®Google Scholar
• Sawata T , BandoM, NakayamaM, MatoN, YamasawaH, SugiyamaY. Influence of smoking in interstitial pneumonia presenting with a nonspecific interstitial pneumonia pattern. Intern. Med.55(20), 2939–2944 (2016).
   PubMed Web of Science ®Google Scholar
• Yamakawa H , HagiwaraE, IkedaSet al. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia. Respir. Investig.57(5), 422–429 (2019).
   PubMed Web of Science ®Google Scholar
• Bennett D , SalviniM, FuiAet al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP. Inflammation42(2), 463–470 (2019).
   PubMed Web of Science ®Google Scholar
• Ichiyasu H , IchikadoK, YamashitaAet al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration83(3), 190–197 (2012).
   PubMed Web of Science ®Google Scholar
• Takahashi T , MunakataM, SuzukiI, KawakamiY. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med.158(4), 1294–1298 (1998).
   PubMed Web of Science ®Google Scholar
• Zhou J , XiaoY, DingJ, ZhouK, ZhouZ, CaiH. [The clinical significance of the levels of serum KL-6 mucin and interleukin-13 in pulmonary alveolar proteinosis]. Zhonghua Jie He He Hu Xi Za Zhi38(2), 110–114 (2015).
   PubMedGoogle Scholar
• Lin FC , ChenYC, ChangSC. Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis. Mayo Clin. Proc.83(12), 1344–1349 (2008).
   PubMed Web of Science ®Google Scholar
• Bonella F , OhshimoS, MiaotianC, GrieseM, GuzmanJ, CostabelU. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet J. Rare Dis.8, 53 (2013).
   PubMed Web of Science ®Google Scholar
• Lanzarone N , GentiliF, AlonziVet al. Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features. Intern Emerg Med.doi: https://doi.org/10.1007/s11739-020-02281-8 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar